Heart ring prices reduce

The government has announced a reduction in the prices of heart rings, a vital medical device for cardiovascular interventions.

The latest price adjustments dictate that the minimum price for a heart ring is set at Tk 20 thousand, while the maximum price is capped at Tk 68 thousand. This development comes as a part of the ongoing efforts to make essential healthcare more accessible and affordable.

The Department of Medicines Administration conveyed this crucial information through an official notification. According to the circular issued, the Directorate General of the Department of Drug Administration engaged in discussions with heart ring (stent) manufacturers from Europe and other countries, alongside interventional cardiologists in Bangladesh. These discussions led to a unanimous decision to reduce the prices of various heart ring models offered by different companies.

Among the notable changes, the price of Poland-made Alex Plus brand stent has been slashed from Tk 80 thousand to Tk 60 thousand. Similarly, the price of Alex brand stent has been brought down from Tk 62,395 to Tk 60 thousand. Additionally, the price adjustments include reductions for stents from other renowned brands like Abaris, Karoflax ISAR, Xilimus, Orsero, Zenos Des, Evascular Angiolite, Ultimaster, and Abluminus Des Plus.

The price revision isn‍‍`t limited to international brands alone; stents manufactured in India have also witnessed significant reductions. Brands like Metaphor, Evermine Fifty, Biomime Morph, and Biomime have seen their prices drop considerably, making them more accessible to patients in need.

Similarly, in the United States, the prices of renowned brands such as Affinity-MS Mini, direct-stent Ciro, and direct-stent have been substantially reduced, further widening access to life-saving medical interventions.

Singapore-made heart ring brands like Biometrics Neoflex, Biometrics Alpha, and Biofreedom have also seen price adjustments, making them more affordable for patients requiring cardiovascular treatments.

These price reductions signify a significant step towards ensuring that essential healthcare services, particularly those related to cardiovascular interventions, are within reach for a broader segment of the population. The move reflects the government‍‍`s commitment to prioritizing public health and well-being by addressing the affordability of critical medical supplies and treatments.